Contact Us
Drug Search Results
More Filters [+]

Lumicitabine

Alternative Names: lumicitabine, jnj-64041575, jnj64041575, jnj 64041575, als-8176, als 8176, als8176, als-008176, als 008176, als008176
Latest Update: 2023-07-19
Latest Update Note: PubMed Publication

Product Description

For Respiratory Syncytial Virus (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03333317)

Mechanisms of Action: Nucleoside Polymerase Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lumicitabine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Respiratory Syncytial Virus Infections|Pneumovirus Infections|Respiratory Sounds|Communicable Diseases

Phase 1: Respiratory Syncytial Virus Infections|Healthy Volunteers|Kidney Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
JapicCTI-173788

P2

Unknown

Respiratory Syncytial Virus Infections

2021-04-30

CR108375

P2

Completed

Respiratory Syncytial Virus Infections|Respiratory Sounds|Communicable Diseases

2020-04-13

JapicCTI-184013

P2

Terminated

Pneumovirus Infections|Respiratory Syncytial Virus Infections

2019-09-30

2017-001696-22

P2

Temporarily not available

Unknown

2019-09-07

Recent News Events

Date

Type

Title

07/19/2023

PubMed

 Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results.

12/01/2022

PubMed

 Nucleoside analogs for management of respiratory virus infections: mechanism of action and clinical efficacy.

07/15/2022

PubMed

 Nitro-Activated Nucleobase Exchange in the Synthesis of 2'-Fluoro-2'-Deoxyribonucleosides.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions